Skip to main content
CG Invites Co., Ltd. logo

CG Invites Co., Ltd. — Investor Relations & Filings

Ticker · 083790 ISIN · KR7083790006 KO Manufacturing
Open in API
Filings indexed 450 across all filing types
Latest filing 2022-03-18 Audit Report / Informat…
Country KR South Korea
Listing KO 083790

About CG Invites Co., Ltd.

https://cginvites.com/en

CG Invites Co., Ltd. is a biopharmaceutical company specializing in digital genomics and personalized medicine. The company's activities are focused on four main areas: genomics, personalized cancer vaccines, digital therapeutics, and the development of chemical and biological drugs. It utilizes Whole Genome Sequencing to support precision medicine initiatives and develops mRNA-based personalized cancer vaccines. The company also creates software-based medical interventions, known as digital therapeutics. Its drug development pipeline includes therapeutics for oncology and inflammatory diseases, such as Acelex for osteoarthritis, Ivaltinostat for pancreatic cancer, and Camrelizumab for immuno-oncology. The company's research approach is based on structural chemoproteomics and the integration of genomic data to develop targeted treatments.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed with the Korean regulatory authority (KRX). It provides the audit opinion (적정/Unqualified), financial highlights (assets, liabilities, equity, profit/loss), and details regarding the auditor (삼화회계법인). While it contains financial data, it is a regulatory disclosure announcement of the audit results rather than the full annual report (10-K) or a standalone audit report document (AR). In the context of Korean regulatory filings, this specific disclosure format is classified as a regulatory filing (RNS). FY 2021
2022-03-18 Korean
사업보고서 (2021.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for CrystalGenomics Inc. for the fiscal year ending December 31, 2021. It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Comprehensive Income Statement, Statement of Changes in Equity, Statement of Cash Flows), and notes to the financial statements. It is not an Annual Report (10-K) as it lacks the comprehensive management discussion and analysis (MD&A) and business overview typically found in a full 10-K, and it is not an announcement (RPA) because it contains the full financial data and audit opinion. FY 2021
2022-03-18 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) issued by CrystalGenomics Inc. It contains the agenda for the upcoming annual general meeting, including the approval of financial statements, election of directors, and other corporate governance matters. It also includes detailed management reports and business overviews as required by Korean commercial law for shareholder meetings. This document is a formal proxy statement/notice for an AGM, which falls under the 'Proxy Solicitation & Information Statement' category.
2022-03-14 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit proxies from shareholders for an upcoming Annual General Meeting (AGM). It contains the agenda, details on voting procedures, and financial information for the meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2022-03-14 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and legal basis. This type of disclosure regarding capital structure changes and equity-based compensation falls under the 'Regulatory Filings' category as it is a specific corporate disclosure required by Korean financial regulations that does not fit into the other specialized categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes).
2022-03-11 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by CrystalGenomics. It outlines the date, location, and agenda items (such as financial statement approval, board compensation, and stock option grants) for the upcoming Annual General Meeting. This type of document is a standard proxy solicitation/information statement provided to shareholders to inform them of meeting details and agenda items.
2022-03-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.